Eli Lilly & Co. is promising big things, but has optimism in the stock gotten ahead of reality? It's time to ask if now's the right time to invest.
Amgen is developing a biosimilar of AbbVie's Humira.
Gilead Science's Tybost and Vitekta are already part of its approved quad pill Stribild.
U.K.-based Big Pharma stocks GlaxoSmithKline and AstraZeneca have some of the juiciest dividends within the healthcare sector; but how sustainable are these yields? Find out which of these two is the better dividend stock.
Botox-maker Allergan has attracted activist investors in droves lately. Here's why.
But smaller biotechs Clovis Oncology and Exelixis also benefit from the big boys' data.
There's a silver lining in CVS's data on Gilead Sciences' Sovaldi.
The healthcare version of Where the Money Is.
Merck gains FDA approval for Keytruda, but the race isn't over yet.
Celgene shares are up more than 1,200% over the past decade. But these three headwinds could be the brick wall that sends its stock lower.